
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Supplements and Featured Publications
over 24 years ago
Participating Facultyover 24 years ago
CME/CPE Quiz





